Table 2.
| 2a. Association of Lipoprotein(a) with Incident Cardiovascular Disease in Women Not Taking Hormone Replacement Therapy | ||||||
|---|---|---|---|---|---|---|
| Quintiles | ||||||
| Lipoprotein (a) | 1 | 2 | 3 | 4 | 5 | P trend |
| Lp(a) median (range), mg/dL* | 2.10 (0.10–3.90) | 6.00 (4.00–8.30) | 11.70 (8.40–16.70) | 25.90 (16.80–45.30) | 66.35 (45.40–239.60) | |
| Women Not taking Hormone Replacement Therapy n=15,661 | ||||||
| No of events | 95 (3.0%) | 86 (2.8%) | 81 (2.6%) | 97 (3.1%) | 166 (5.3%) | |
| Person-years of follow-up | 31 395 | 30 877 | 30 999 | 30 723 | 30 549 | |
| HR (95% CI) (age-adjusted) | 1 | 0.93 (0.70, 1.25) | 0.82 (0.61, 1.10) | 0.95 (0.72, 1.26) | 1.67 (1.30, 2.15) | <0.0001 |
| HR (Framingham-adjusted)† | 1 | 0.93 (0.69, 1.24) | 0.82 (0.60, 1.10) | 0.90 (0.67, 1.20) | 1.64 (1.27, 2.12) | <0.0001 |
| HR (Fully-adjusted)‡ | 1 | 0.97 (0.72, 1.31) | 0.92 (0.68, 1.26) | 0.97 (0.72, 1.30) | 1.77 (1.36, 2.30) | <0.0001 |
| 2b. Lipoprotein (a), LDL-C and Hazard Ratios of Future Cardiovascular Events Among Women Not Taking Hormone Replacement Therapy | ||||||
|---|---|---|---|---|---|---|
| Quintiles | ||||||
| Lipoprotein (a) | 1 | 2 | 3 | 4 | 5 | P trend |
| Lp(a) median (range), mg/dL* | 2.10 (0.10–3.90) | 6.00 (4.00–8.30) | 11.70 (8.40–16.70) | 25.90 (16.80–45.30) | 66.35 (45.40–239.60) | |
| Women Not Taking Hormone Replacement Therapy with LDL-C≥ median†n=8269 | ||||||
| No. of CV Events | 55 (3.8%) | 50 (3.4%) | 58 (3.6%) | 67 (3.8%) | 139 (6.9%) | |
| Person-years of follow-up | 14 184 | 14 501 | 15 766 | 17 370 | 19 540 | |
| HR (95% CI) (age-adjusted) | 1 | 0.91 (0.62, 1.34) | 0.93 (0.64, 1.35) | 0.94 (0.66, 1.35) | 1.80 (1.32, 2.46) | <0.0001 |
| HR (Framingham-adjusted)‡ | 1 | 0.89 (0.61, 1.31) | 0.91 (0.62, 1.31) | 0.90 (0.62, 1.29) | 1.87 (1.36, 2.56) | <0.0001 |
| HR (fully-adjusted)§ | 1 | 0.99 (0.67, 1.48) | 1.04 (0.71, 1.53) | 1.03 (0.71, 1.50) | 2.06 (1.49, 2.86) | <0.0001 |
| Women Not Taking Hormone Replacement Therapy with LDL-C< median† n=7392 | ||||||
| No. of CV Events | 40 (2.3%) | 36 (2.2%) | 23 (1.5%) | 30 (2.2%) | 27 (2.4%) | |
| Person-years of follow-up | 17 211 | 16 376 | 15 233 | 13 353 | 11 010 | |
| HR (95% CI) (age-adjusted) | 1 | 0.95 (0.60, 1.49) | 0.60 (0.36, 1.00) | 0.91 (0.57, 1.46) | 1.07 (0.66, 1.74) | 0.45 |
| HR (Framingham-adjusted) | 1 | 0.99 (0.63, 1.56) | 0.67 (0.40, 1.13) | 0.98 (0.60, 1.58) | 1.18 (0.72, 1.93) | 0.30 |
| HR (fully-adjusted)§ | 1 | 0.92 (0.58, 1.47) | 0.77 (0.46, 1.30) | 0.89 (0.54, 1.48) | 1.25 (0.76, 2.06) | 0.23 |
Lp(a) quintile levels were derived from the stratum of women not taking hormone replacement therapy.
Framingham-adjusted model refers to adjustments for covariates age, blood pressure categories, current smoking status, total cholesterol and high-density lipoprotein values.
Fully-adjusted models refer to Framingham covariates of age, blood pressure categories, current smoking status, total cholesterol and high density lipoprotein values as well as body mass index, diabetes, C-reactive protein and treatment arms.
Lp(a) quintile levels were derived from women not taking hormone replacement therapy.
Median LDL-C value was 121.4 mg/dL.
Framingham-adjusted model refers to adjustments for covariates age, blood pressure categories, current smoking status, total cholesterol and high-density lipoprotein values.
Fully-adjusted models refer to Framingham covariates of age, blood pressure categories, current smoking status, total cholesterol and high density lipoprotein values as well as body mass index, diabetes, C-reactive protein and treatment arms.